Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Eczema: What Does It Look Like & How Can I Treat It?
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
Fierce Biotech7d
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Healthline8d
An Expert Explains Signs It’s Time to Try a Biologic for Eczema
Eczema can be managed with certain self-care ... or mycophenolate mofetil Biologic agents, such as dupilumab (Dupixent) or lebrikizumab-lbkz (Ebglyss), are reserved for people who have tried ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Hosted on MSN12d
Biologic May Spark Catch-Up Growth in Kids With Eczema
children ages 6 to 11 years who were in every height category from under the 39th percentile to under the 25th percentile ...
Yahoo Finance9d
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...
Business Insider9d
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...